VIR News and Press, Vir Biotechnology Inc. From 03/13/24

2024-03-13 11:07:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interes...

– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter – – Approximately 50% of participants have compensated cirrhosis – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clin...

2024-02-26 06:55:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It’s also fairly easy to identify such sto...

2024-02-23 10:00:17 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...

2024-02-22 20:49:13 ET More on etc. Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript Hooker Furnishings: Temporary Headwinds Haven't Created An Attractive Buying Level MP Materials Corp. (MP) Q4 2023 Earnings Call Transcript Crude oil edges high...

2024-02-22 20:48:06 ET Vir Biotechnology, Inc. (VIR) Q4 2023 Results Conference Call February 22, 2024 04:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Ph...

2024-02-22 16:27:48 ET More on Vir Biotechnology Sticking With Vir Biotechnology JP Morgan cuts Vir to neutral, cites hepatitis drug franchise concerns Vir Biotechnology to shed 12% of workforce as part of corporate restructuring Seeking Alpha’s Quant ...

– Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification – – Phase 2 SOLSTICE trial on track to...

2024-02-20 16:33:24 ET More on Vir Biotechnology Sticking With Vir Biotechnology JP Morgan cuts Vir to neutral, cites hepatitis drug franchise concerns Vir Biotechnology to shed 12% of workforce as part of corporate restructuring Read the full article on Se...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor. “Phi...